Skip to content

News

The Institute generates news every day. Some findings are groundbreaking—some represent smaller steps. But ultimately, it is the combination of both that makes scientific advancement possible. Here is a little selection of the latest stories making it out to the wider world.

Filter by:

Keyword

Showing

Gut microbiome key to immunotherapy success: new “Cell” study reveals mechanisms of individual molecules

28.09.2026

Immunotherapies, especially CAR T-cell therapy, have fundamentally changed cancer treatment in recent years, particularly for certain forms of leukemia and lymphoma. Yet not all tumors respond equally well, and the reasons for this remain incompletely understood. A new multicenter study by the LIT collaboration group “Innate Immune Sensing in Cancer and Transplantation” now shows that it is not only the composition of the gut microbiota that determines the success of CAR T-cell therapy, but above all its metabolic products. As reported in the current issue of the journal “Cell”, certain microbial metabolites can enhance or inhibit CAR T-cell function, with a major impact on treatment outcome. They also offer important starting points for microbiome-based therapies and dietary strategies aimed at supporting the gut microbiome during cancer treatment.

Nearly €5 Million for New AI Infrastructure in Health and Prevention Research

22.09.2026

The Federal Ministry of Research, Technology and Space (BMFTR) is funding the development of a new computing infrastructure for health and prevention research. The three-year project will receive nearly €5 million in funding. It is one of three AI infrastructure projects supported by the Leibniz Association under the Global Minds Initiative Germany. Together, the three projects have a combined funding volume of approximately €14.9 million. The project is closely linked to the “Leibniz Health & Prevention” initiative, in which the LIT plays a leading role.

Medicine of the Future: “Leibniz Health & Prevention” Initiative Presented at MS Wissenschaft

18.09.2026

During the event “Leibniz Debates: Medicine of the Future” on August 21, 2026 in Mainz aboard the MS Wissenschaft, the “Leibniz Health & Prevention” (LHP) initiative was introduced. This initiative brings together the expertise of Leibniz Institutes focused on biomedical technology to advance preventive, predictive, and precision healthcare. Prof. Philipp Beckhove, Scientific Director of the LIT, is one of two LHP speakers.

“Book A Scientist”: Speed Dating with LIT researchers

08.09.2026

With “Book a Scientist,” you have the chance to spend 25 minutes talking with an expert from the LIT and asking everything you’ve always wanted to know about your favorite topic. But it’s not just the LIT that’s answering questions from the public – there are participants from all areas of the Leibniz Association. Choose from over 100 topics for your conversation.

The Power of T Cells: Leibniz Magazine Visits the Leibniz Institute for Immunotherapy

17.08.2026

They can destroy, slow down, and heal — and may yet reshape medicine in fundamental ways. At the Leibniz Institute for Immunotherapy (LIT) in Regensburg, researchers are working to better understand T cells and to harness them for the treatment of cancer and autoimmune diseases. The latest issue of leibniz – the magazine of the Leibniz Association, published under the theme “Medicine”, takes up this research in a feature article that includes a guided tour of the institute.

CAR T-REX EU Consortium: Meeting at the LIT

22.07.2026

Following the LIT Symposium, the CAR T-REX EU consortium gathered for its 2026 annual in-person meeting at the LIT in Regensburg in June 2026. The day featured scientific presentations, technical discussions and a tour through the LIT facilities, offering participants a closer look at the team’s work on the generation and characterization of CAR T cells targeting solid tumors.